论文部分内容阅读
目的探讨循环肿瘤干细胞与原发性乳腺癌患者生存时间的相关性。方法对50例乳腺癌患者的外周血进行免疫组化检测,对患者进行随访,分析两者之间的关系。结果 50例患者中,CK19+/CD44+/CD24-/LOW阳性36例,阴性14例。乳腺癌组织上皮细胞的CK19+/CD44+/CD24-/LOW表达率明显高于癌旁组织,差异有统计学意义(P<0.05)。50例乳腺癌外周血标本中,Cerb B-2高表达患者癌组织中CK19+/CD44+/CD24-/LOW阳性表达率为85.2%(23/27),C-erb B-2低表达患者癌组织中CK19+/CD44+/CD24-/LOW阳性表达率为39.1%(9/23),且C-erb B-2表达强度随CK19+/CD44+/CD24-/LOW阳性率增加而增高,两组差异有统计学意义(P<0.05)。随CK19+/CD44+/CD24-/LOW表达的增高,患者发生远处转移及死亡率增高。结论动态监测循环肿瘤干细胞变化,有利于及时了解乳腺癌患者病情及治疗效果。
Objective To investigate the relationship between circulating cancer stem cells and survival time of patients with primary breast cancer. Methods Immunohistochemical detection of peripheral blood in 50 patients with breast cancer was performed. The patients were followed up and the relationship between them was analyzed. Results Of the 50 patients, CK19 + / CD44 + / CD24- / LOW were positive in 36 cases and negative in 14 cases. The positive rate of CK19 + / CD44 + / CD24- / LOW in breast cancer epithelial cells was significantly higher than that in paracancerous tissues (P <0.05). The positive rate of CK19 + / CD44 + / CD24- / LOW was 85.2% (23/27) in cancerous tissues of Cerb B-2 overexpression in 50 cases of breast cancer. The expression of C-erb B-2 in cancerous tissues The positive rate of CK19 + / CD44 + / CD24- / LOW was 39.1% (9/23), and the expression of C-erb B-2 increased with the increase of positive rate of CK19 + / CD44 + / CD24- / LOW Significance (P <0.05). With the increase of CK19 + / CD44 + / CD24- / LOW expression, patients with distant metastasis and increased mortality. Conclusion Dynamic monitoring of circulating tumor stem cells changes is conducive to timely understanding of breast cancer patients and treatment.